Search Results

Eckert & Ziegler and Nucleus RadioPharma signed extensive supply agreements for major therapeutic radioisotopes.

Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, announced that it has received encouraging feedback from the U.S. FDA following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registration study with its radiopharmaceutical diagnostic Ga68-PentixaFor in Primary Aldosteronism.

Eckert & Ziegler and PharmaLogic Holdings Corp. have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225.

Eckert & Ziegler and a subsidiary of POINT Biopharma Global Inc. have signed an agreement on the supply of Actinium-225.

RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, has expanded its radiopharmaceutical contract development and manufacturing

NorthStar Medical Radioisotopes, LLC and Eckert & Ziegler Isotope Technologies Dresden announced an agreement for the purchase of hot cells and related equipment for NorthStar’s dedicated non-carrier-added actinium-225 production facility.

Telix Pharmaceuticals Limited announces a global clinical supply agreement with Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG for highly pure no-carrier-added lutetium-177, a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation investigational products.

Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these six biotechs are playing in the largely underappreciated longevity space, developing therapies that may improve the quality of aging.